Literature DB >> 22980313

Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: a study from the Pediatric Cardiomyopathy Registry.

James D Wilkinson1, April M Lowe, Bonnie A Salbert, Lynn A Sleeper, Steven D Colan, Gerald F Cox, Jeffrey A Towbin, David M Connuck, Jane E Messere, Steven E Lipshultz.   

Abstract

BACKGROUND: Studies of cardiomyopathy in children with Noonan syndrome (NS) have been primarily small case series or cross-sectional studies with small or no comparison groups.
METHODS: We used the Pediatric Cardiomyopathy Registry database to compare the survival experience of children with NS and hypertrophic cardiomyopathy (HCM) with children with idiopathic or familial HCM and to identify clinical and echocardiographic predictors of clinical outcomes.
RESULTS: Longitudinal data in 74 children with NS and HCM and 792 children with idiopathic or familial isolated HCM were compared. Children with NS were diagnosed with HCM before 6 months old more often (51%) than children with HCM (28%) and were more likely to present with congestive heart failure (CHF) (24% vs 9%). The NS cohort had lower crude survival than the group with other HCM (P = .03), but survival did not differ after adjustment for CHF and age at diagnosis. Within the NS cohort (1-year survival 78%), a diagnosis of HCM before age 6 months with CHF resulted in 31% 1-year survival. Lower height-for-age z score (hazard ratio 0.26, P = .005) in place of CHF and lower left ventricular fractional shortening z score (hazard ratio 0.79, P = .04) also independently predicted mortality.
CONCLUSIONS: Patients with NS with HCM have a worse risk profile at presentation compared with other children with HCM, resulting in significant early mortality (22% at 1 year). Decreased height-for-age and lower, although still supranormal, left ventricular fractional shortening z score are independent predictors of mortality in patients with NS with HCM. Such patients should have an aggressive therapeutic approach including potential listing for cardiac transplantation.
Copyright © 2012 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22980313     DOI: 10.1016/j.ahj.2012.04.018

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  33 in total

1.  Mitral valve replacement and trans-mitral myectomy for a child with Noonan syndrome accompanied by hypertrophic obstructive cardiomyopathy.

Authors:  Takashi Sasaki; Toshihide Asou; Makoto Shirakawa; Ken-Ichiro Takahashi; Shinobu Kunugi; Takashi Nitta
Journal:  Gen Thorac Cardiovasc Surg       Date:  2019-02-19

2.  Risk stratification at diagnosis for children with hypertrophic cardiomyopathy: an analysis of data from the Pediatric Cardiomyopathy Registry.

Authors:  Steven E Lipshultz; E John Orav; James D Wilkinson; Jeffrey A Towbin; Jane E Messere; April M Lowe; Lynn A Sleeper; Gerald F Cox; Daphne T Hsu; Charles E Canter; Juanita A Hunter; Steven D Colan
Journal:  Lancet       Date:  2013-09-03       Impact factor: 79.321

3.  Congenital heart defects in Noonan syndrome: Diagnosis, management, and treatment.

Authors:  Léa Linglart; Bruce D Gelb
Journal:  Am J Med Genet C Semin Med Genet       Date:  2020-02-05       Impact factor: 3.908

Review 4.  Pediatric Cardiomyopathies.

Authors:  Teresa M Lee; Daphne T Hsu; Paul Kantor; Jeffrey A Towbin; Stephanie M Ware; Steven D Colan; Wendy K Chung; John L Jefferies; Joseph W Rossano; Chesney D Castleberry; Linda J Addonizio; Ashwin K Lal; Jacqueline M Lamour; Erin M Miller; Philip T Thrush; Jason D Czachor; Hiedy Razoky; Ashley Hill; Steven E Lipshultz
Journal:  Circ Res       Date:  2017-09-15       Impact factor: 17.367

5.  Hypertrophic Cardiomyopathy in Noonan Syndrome Treated by MEK-Inhibition.

Authors:  Gregor Andelfinger; Christopher Marquis; Marie-Josée Raboisson; Yves Théoret; Stephan Waldmüller; Gesa Wiegand; Bruce D Gelb; Martin Zenker; Marie-Ange Delrue; Michael Hofbeck
Journal:  J Am Coll Cardiol       Date:  2019-05-07       Impact factor: 24.094

6.  Inducible Pluripotent Stem Cell-Derived Cardiomyocytes Reveal Aberrant Extracellular Regulated Kinase 5 and Mitogen-Activated Protein Kinase Kinase 1/2 Signaling Concomitantly Promote Hypertrophic Cardiomyopathy in RAF1-Associated Noonan Syndrome.

Authors:  Fabrice Jaffré; Clint L Miller; Anne Schänzer; Todd Evans; Amy E Roberts; Andreas Hahn; Maria I Kontaridis
Journal:  Circulation       Date:  2019-06-05       Impact factor: 29.690

7.  Cardiac Manifestations and Associations with Gene Mutations in Patients Diagnosed with RASopathies.

Authors:  Won Kyoung Jhang; Jin-Ho Choi; Beom Hee Lee; Gu-Hwan Kim; Han-Wook Yoo
Journal:  Pediatr Cardiol       Date:  2016-08-23       Impact factor: 1.655

Review 8.  Importance of genetic evaluation and testing in pediatric cardiomyopathy.

Authors:  Muhammad Tariq; Stephanie M Ware
Journal:  World J Cardiol       Date:  2014-11-26

9.  Cardiomyopathies in Noonan syndrome and the other RASopathies.

Authors:  Bruce D Gelb; Amy E Roberts; Marco Tartaglia
Journal:  Prog Pediatr Cardiol       Date:  2015-07-01

10.  Frequency of aortic dilation in Noonan syndrome.

Authors:  James W Cornwall; Robert S Green; James C Nielsen; Bruce D Gelb
Journal:  Am J Cardiol       Date:  2013-10-04       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.